Evidence map›Paper›PMID 40944992›Full record

Observational studyESMO open2025

Clinical characteristics and prognosis of pulmonary lymphoepithelioma-like carcinoma: a multicenter cohort study of 1106 cases.

Z Hou, M Lan, Y-X Zhu, Z-H Xue, M He, R-X Ma, S Liu, L Wu, Y Wang, G Wan and 3 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Z HouDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. Electronic address: https://twitter.com/medicalchengdu.
M LanDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Y-X ZhuDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Z-H XueDepartment of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People's Hospital (The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, China.
M HeDepartment of Oncology, Deyang People's Hospital, Deyang, China.
R-X MaDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
S LiuDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
L WuDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Y WangDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
G WanDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
B-S LiDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
B-Q ChenDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China; United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Ltd, Guangzhou, China. Electronic address: chenbaoqing@sysucc.org.cn.
Q-F WangDepartment of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. Electronic address: wangqifeng@scszlyy.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare form of squamous lung cancer with clinical features that have conflicting findings from different studies. Meanwhile, the survival time, pattern of failure after treatment, and independent prognostic factors of these patients need to be further confirmed by large-sample studies, and whether their treatment regimens need to be different from those of squamous lung cancer remains unknown. PATIENTS AND

methodsPatients with PLELC diagnosed by pathology from January 2009 to December 2023 at four medical centers in China were retrospectively analyzed.

resultsA total of 1106 patients with PLELC were enrolled in the study. Of these patients, 0.3% (3/1106) had brain metastasis, and 71.6% (176/204) tested positive for programmed death-ligand 1 (PD-L1). The 2-year overall survival (OS) rates of stage I, II, III, and IV were 99.4%, 97.7%, 92.7%, and 70.4%, respectively, and the 5-year OS rates were 94.8%, 88.7%, 70.6%, and 37.8%, respectively. cTNM (clinical tumor-node-metastasis) stage and baseline Epstein-Barr virus (EBV) DNA level were independent prognostic factors for both PFS and OS in PLELC patients. No statistically significant differences in progression-free survival (PFS) or OS were observed between surgery alone and surgery with adjuvant therapy in stage I and II patients or between chemoradiotherapy and combined surgery-radiotherapy in stage IIIA and IIIB patients. In stage IV patients, chemoimmunotherapy appears to have longer PFS and OS than chemotherapy alone.

conclusionsPLELC patients, with rare brain metastasis and high PD-L1 positivity, show favorable prognosis, but further research is needed to refine optimal treatment strategies for PLELC.

Indexed as

Lung NeoplasmsAdultAgedChinaCohort StudiesFemaleHumansMaleMiddle AgedPrognosisRetrospective Studiesclinical featuresprognosispulmonary lymphoepithelioma-like carcinoma

Identifiers

PMID40944992
PMCPMC12573445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.